Table 1 Patient characteristics in the EPITAX, DDP and PETREMAC clinical trials
From: Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
| Â | EPITAX (N = 99) | DDP (N = 95) | PETREMAC (N = 217) |
|---|---|---|---|
Age | |||
 Mean (SD) | 49.5 (10.3) | 48.4 (9.80) | 53.0 (10.9) |
 Median [Min, Max] | 49.0 [25.0, 70.0] | 48.0 [24.0, 71.0] | 51.0 [27.0, 78.0] |
Tumor receptor status * | |||
 TNBC | 16 (16.2%) | 17 (17.9%) | 33 (15.2%) |
 HER2–/ER<10% | 4 (4.0%) | 0 | 2 (0.9%) |
 HER2–/ER≥10% | 48 (48.5%) | 59 (62.1%) | 114 (52.5%) |
 HER2+ | 29 (29.3%) | 19 (20.0%) | 68 (31.3%) |
 Missing | 2 (2.0%) | 0 | 0 |
Tumor molecular subtype * | |||
 Basal | 24 (24.2%) | 14 (14.7%) | 29 (13.4%) |
 Her2 | 20 (20.2%) | 14 (14.7%) | 45 (20.7%) |
 LumA | 22 (22.2%) | 32 (33.7%) | 70 (32.3%) |
 LumB | 22 (22.2%) | 25 (26.3%) | 51 (23.5%) |
 Normal | 11 (11.1%) | 10 (10.5%) | 20 (9.2%) |
 Missing | 0 | 0 | 2 (0.9%) |
Tumor histology | |||
 IDC | 80 (80.8%) | 72 (75.8%) | 159 (73.3%) |
 ILC | 15 (15.2%) | 17 (17.9%) | 32 (14.7%) |
 Other | 4 (4.0%) | 6 (6.3%) | 26 (12.0%) |